Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.

© Juan Diego Reyes for The New York Times

Z.ai confirms it is behind Ox Alpha, the mysterious open AI model topping benchmarks and leaderboards, and its weights are set to be released soon.